Latest Post

The Top Ingredients to Look For in Menopausal Skin-Care Probiotics: Solving Poor Digestive Health How to Do Double Leg Lift in Pilates? Tips, Technique, Correct Form, Benefits and Common Mistakes Top 5 Emerging Skincare Markets in 2022: Brazil, China, India, Mexico and South Africa – Market Summary, Competitive Analysis and Forecast to 2025 – ResearchAndMarkets.com Kelvin Harrison Jr. Is Growing with the Flow

DUBLIN, May 09, 2022–(BUSINESS WIRE)–The “Diabetic Retinopathy Market by Type (Proliferative Diabetic Retinopathy, Diabetic Macular Edema), and Treatment Type: Global Opportunity Analysis and Industry Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.

The global diabetic retinopathy market was valued at $3,086.00 million in 2020, and is projected to reach $10,785.50 million by 2030, registering a CAGR of 13.7% from 2021 to 2030.

Diabetic retinopathy is blood vessel damage in the retina that happens as a result of diabetes. Diabetic retinopathy can cause a range of symptoms, including blurred vision, difficulty seeing colors, and eye floaters. Without treatment, it can cause vision loss. Diabetic retinopathy is the leading cause of new cases of blindness in adults, as well as the most common cause of vision loss for people with diabetes. People may not have any early symptoms of diabetic retinopathy.

The diabetic retinopathy market has witnessed tremendous growth owing to technological advancements in the ophthalmic surgical and diagnostic instruments. Moreover, optical coherence tomography and other technologically upgraded devices utilized in diagnosis provide superior quality cross-sectional images that allow doctor to make better decisions. In addition, surgical instruments have enhanced precision that improves the surgery success rates.

Thus, availability of such upgraded ophthalmic devices and instruments have facilitated the diagnostic and surgical procedures that positively impact the industry growth. However, complications and adverse reactions associated with the medications prescribed for minimizing the impact of diabetic retinopathy may hamper the industry growth to some extent.

Increase in the geriatric populations, rise in focus and awareness of early diagnosis in order to control the growth of the disease, surge in prevalence of diabetes, and growth in incidence of blindness due to diabetes drive the growth of the market. However, this growth is limited by the dearth of skilled ophthalmologists and extended approval time for drugs.

Conversely, emergence of combined therapies for treatment of diabetic macular edema and the emerging markets of Asia-Pacific and LAMEA are expected to provide several opportunities for market growth during the forecast period.

Region wise, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2020, owing to high prevalence of DR in this region, coupled with well-established infrastructure and increasing initiatives by the government to create awareness that would help people undergo screening for DR.

However, Asia-Pacific is expected to witness considerable market growth during the forecast period, due to high population base, high disposable incomes, and improvement in patient awareness about the treatment of diabetic retinopathy.

Key Findings Of Study

  • By type, the proliferative diabetic retinopathy segment currently dominates the global diabetic retinopathy market and is expected to continue during the forecast period owing to increasing prevalence of the medical condition worldwide. Globally, in 2017, among adults aged 45 and over withdiagnosed diabetes, 32.2% had cataracts, 8.6% had diabetic retinopathy, 7.1% had glaucoma, and 4.3% had macular degeneration This can serve as a major opportunity for manufacturers to capitalize and expand their market share

  • By treatment type, the laser surgeries segment dominated the global diabetic retinopathy market in 2020 and is anticipated to be dominant in the market. Since this treatment type has been available in the market for a long period, there is high acceptance and familiarity with the procedure Thus, laser surgeries serve to be the lucrative investment pocket

  • On the basis of region, in 2020, North America dominated the market in 2020, owing to high prevalence of DR in this region, coupled with well-established infrastructure and increasing initiatives by the government to create awareness that would help people undergo screening for DR However, Asia-Pacific is expected to witness considerable diabetic retinopathy market growth during the forecast period, due to high population base, high disposable incomes, and improvement in patient awareness about the treatment of diabetic retinopathy

The major players operating in the global Diabetic Retinopathy market are

  • Alimera Science, Inc

  • Abbvie, Inc

  • Ampio Pharmaceuticals, Inc

  • Bayer AG

  • Kowa Co,Ltd

  • Novartis

  • Pfizer, Inc

  • Regeneron Pharmaceuticals, Inc

  • F-Hoffmann-La Roche Ltd

  • Valeant Pharmaceuticals International, Inc (Bausch Health Companies Inc)

KEY MARKET SEGMENTS

By Type

By Treatment Type

  • Anti-VEGF Drug

  • steroid implants

  • Laser surgeries

  • vitrectomy

By region

  • NorthAmerica

  • U.S

  • Canada

  • Mexico

  • Europe

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Rest of Europe

  • Asia Pacific

  • Japan

  • China

  • Australia

  • India

  • south korea

  • Rest of Asia Pacific

  • LAMEA

  • Brazil

  • Saudi Arabia

  • South Africa

  • Rest of LAMEA

For more information about this report visit https://www.researchandmarkets.com/r/eh6ws6

View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005585/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For US/CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: